Daily non-political popular news in brief.

SCAI leaders available for comment on studies released at European Society for Cardiology Congress

New studies and clinical trials and data to be released on interventional cardiology, percutaneous intervention (PCI), including use of angioplasty, renal artery stenting, bare metal stents and drug eluting stents.

Read more »

Keywords: scai, leaders, available, comment, studies, released, european, society, cardiology, congress, leader, study

« Previous | Next »

Similar news on "SCAI leaders available for comment on studies released at European Society for Cardiology Congress":

1. Release of new guidelines on the management of arterial hypertension
   06-13-2007 · EurekAlert!
   The European Society of Cardiology and the European Society of Hypertension have released new guidelines on the management of Arterial Hypertension.
   Similar news · Read more »
   
2. SCAI leaders say courage results unlikely to change use of PCI
   03-27-2007 · EurekAlert!
   Results of the COURAGE trial, presented today at the American College of Cardiology Annual Scientific Session, are unlikely to alter the approach that interventional cardiologists take in treating most patients with chronic stable angina, say leaders from the Society for Cardiovascular Angiography and Interventions (SCAI), the leading professional society for interventional cardiologists in the United States.
   Similar news · Read more »
   
3. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
   09-03-2007 · EurekAlert!
   The largest-ever study of treatments for type 2 diabetes has shown that a combination of two blood pressure lowering drugs reduced the risk of death, as well as the risks of heart and kidney disease. The ADVANCE (Action in Diabetes and Vascular Disease) Study was led by researchers at the George Institute for International Health in Sydney and the results have been presented at the European Congress of Cardiology in Vienna.
   Similar news · Read more »
   
4. Call for greater use of comparative effectiveness studies to help advance disease management
   04-03-2007 · EurekAlert!
   The largest retrospective, observational study comparing two osteoporosis therapies on the basis of fracture reduction was presented today at the Seventh European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO) in Porto, Portugal. Patients taking the osteoporosis treatment risedronate (Actonel, risedronate sodium) were almost half as likely to sustain a hip fracture as those taking alendronate in the first year of treatment, according to the REAL (RisedronatE, ALendronate) study.
   Similar news · Read more »
   
5. Complex ART procedures more likely to lead to umbilical cord abnormality
   07-04-2007 · EurekAlert!
   The more complex the assisted reproduction procedure, the more likely the umbilical cord develops in an atypical place or have other abnormalities, a scientist told the 23rd Annual Conference of the European Society of Human Reproduction and Embryology today (Wednesday, July 4). Mrs. Ilse Delbaere, from Ghent University Hospital, Ghent, Belgium, said that the study, including over 4000 twin pregnancies, was the first to examine umbilical cord abnormalities in such a large population.
   Similar news · Read more »
   
6. Heart failure medication provides some symptom relief
   03-25-2007 · EurekAlert!
   A medication used to treat heart failure, tolvaptan, appears to improve some symptoms and signs of heart failure during hospitalization, but does not reduce the risk of re-hospitalization or death, according to two articles in the March 28 issue of JAMA. The study is being released early to coincide with its presentation at the American College of Cardiology's annual conference.
   Similar news · Read more »
   
7. Combination HDL/LDL therapy has no effect on plaque build-up
   03-26-2007 · EurekAlert!
   Two RADIANCE studies presented today at the American College of Cardiology's 56th Annual Scientific Session assessed the effects of adding torcetrapib to atorvastatin among patients to improve their cholesterol levels. Although the ILLUMINATE study and other trials involving torcetrapib were recently stopped because of safety concerns, the effect of the drug on carotid intima-media thickness (CIMT) may provide useful information on whether it slows the progression of atherosclerosis.
   Similar news · Read more »
   
8. Preliminary results suggest Certolizumab Pegol is effective in reducing signs and symptoms
   06-14-2007 · EurekAlert!
   Fifty-nine percent of patients receiving certolizumab pegol 200mg plus methotrexate, and 61 percent of patients receiving certolizumab pegol 400mg plus methotrexate every two weeks achieved a 20 percent improvement in symptoms (known as an American College of Rheumatology 20 Response) after 24 weeks' treatment, according to a study presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain. Only 14 percent of patients receiving methotrexate alone achieved an ACR20 response over the same period, highlighting the superiority of the treatment combination at both doses of certolizumab pegol in patients refractory to methotrexate.
   Similar news · Read more »
   
9. What makes a good leader -- the assertiveness quotient
   02-04-2007 · EurekAlert!
   Organizational leaders who come across as low or high in assertiveness tend to be seen as less effective, according to a study coming out in the February issue of the Journal of Personality and Social Psychology, published by the American Psychological Association. Leaders in the middle may have an "optimal" level of assertiveness, but there is plenty of company on the extremes. The research suggests that being seen as under- or over-assertive may be the most common weakness among aspiring leaders.
   Similar news · Read more »
   
10. SCAI expert panel sets high standards for PCI without on-site cardiac surgical back-up
    02-05-2007 · EurekAlert!
    The Society for Cardiovascular Angiography and Interventions (SCAI), a leading organization for interventional cardiologists, today released a document recommending the adoption of stringent quality standards by those who perform percutaneous coronary intervention (PCI) in hospitals not equipped for cardiac surgery. The document has been endorsed by 12 medical societies representing more than a dozen countries, including the Asia-Pacific region, Australia, Belgium, Brazil, Bulgaria, Egypt, Great Britain, India, Italy, Latvia, New Zealand, Poland and Venezuela.
    Similar news · Read more »